Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity

被引：71

作者：

Ritchie, Marylyn D.

Haas, David W.

Motsinger, Alison A.

Donahue, John P.

Erdem, Huso

Raffanti, Stephen

Rebeiro, Peter

George, Alfred L.

Kim, Richard B.

Haines, Jonathan L.

Sterling, Timothy R.

机构：

[1] Vanderbilt Univ, Sch Med, Ctr Human Genet Res, Nashville, TN 37232 USA

[2] Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA

[3] Vanderbilt Univ, Sch Med, Dept Med, Div Infect Dis, Nashville, TN 37232 USA

[4] Vanderbilt Univ, Sch Med, Dept Immunol & Microbiol, Nashville, TN 37232 USA

[5] Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA

[6] Vanderbilt Univ, Sch Med, Comprehens Care Ctr, Nashville, TN 37232 USA

[7] Vanderbilt Univ, Sch Med, Ctr Hlth Serv Res, Nashville, TN 37232 USA

来源：

CLINICAL INFECTIOUS DISEASES | 2006年 / 43卷 / 06期

关键词：

MULTIFACTOR DIMENSIONALITY REDUCTION; P-GLYCOPROTEIN; NEVIRAPINE; PHARMACOGENETICS;

D O I：

10.1086/507101

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

This nested case-control study examined relationships between MDR1, CYP2B6, and CYP3A4 variants and hepatotoxicity during antiretroviral therapy with either efavirenz- or nevirapine-containing regimens. Decreased risk of hepatotoxicity was associated with MDR1 3435C -> T ( odds ratio, 0.254;). An interaction between MDR1 and hepatitis B surface antigen status predicted risk with 82% accuracy (P < .001).

引用

收藏

页码：779 / 782

页数：4

相关论文

共 13 条

[1] Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals [J].

Almond, LM ;

Edirisinghe, D ;

Dalton, M ;

Bonington, A ;

Back, DJ ;

Khoo, SH .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (02) :132-142

[2] Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo [J].

Colombo, S ;

Soranzo, N ;

Rotger, M ;

Sprenger, R ;

Bleiber, G ;

Furrer, H ;

Buclin, T ;

Goldstein, D ;

Décosterd, L ;

Telenti, A .

PHARMACOGENETICS AND GENOMICS, 2005, 15 (09) :599-608

[3] Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study [J].

Fellay, J ;

Marzolini, C ;

Meaden, ER ;

Back, DJ ;

Buclin, T ;

Chave, JP ;

Decosterd, LA ;

Furrer, H ;

Opravil, M ;

Pantaleo, G ;

Retelska, D ;

Ruiz, L ;

Schinkel, AH ;

Vernazza, P ;

Eap, CB ;

Telenti, A .

LANCET, 2002, 359 (9300) :30-36

[4] Pharmacogenetics of nevirapine-associated hepatotoxicity: An adult AIDS clinical trials group collaboration [J].

Haas, David W. ;

Bartlett, John A. ;

Andersen, Janet W. ;

Sanne, Ian ;

Wilkinson, Grant R. ;

Hinkle, John ;

Rousseau, Franck ;

Ingram, Christiana D. ;

Shaw, Audrey ;

Lederman, Michael M. ;

Kim, Richard B. .

CLINICAL INFECTIOUS DISEASES, 2006, 43 (06) :783-786

[5] Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir:: An adult AIDS clinical trials group study [J].

Haas, DW ;

Smeaton, LM ;

Shafer, RW ;

Robbins, GK ;

Morse, GD ;

Labbé, L ;

Wilkinson, GR ;

Clifford, DB ;

D'Aquila, RT ;

De Gruttola, V ;

Pollard, RB ;

Merigan, TC ;

Hirsch, MS ;

George, AL ;

Donahue, JP ;

Kim, RB .

JOURNAL OF INFECTIOUS DISEASES, 2005, 192 (11) :1931-1942

[6] Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions [J].

Hahn, LW ;

Ritchie, MD ;

Moore, JH .

BIOINFORMATICS, 2003, 19 (03) :376-382

[7] Appropriate use of nevirapine for long-term therapy [J].

Leith, J ;

Piliero, P ;

Storfer, S ;

Mayers, D ;

Hinzmann, R .

JOURNAL OF INFECTIOUS DISEASES, 2005, 192 (03) :545-546

[8] Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts [J].

Martin, AM ;

Nolan, D ;

James, I ;

Cameron, P ;

Keller, J ;

Moore, C ;

Phillips, E ;

Christiansen, FT ;

Mallal, S .

AIDS, 2005, 19 (01) :97-99

[9] Polymorphisms in human MDR1 (P-glycoprotein):: Recent advances and clinical relevance [J].

Marzolini, C ;

Paus, E ;

Buclin, T ;

Kim, RB .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (01) :13-33

[10]

Motsinger Alison A., 2006, Human Genomics, V2, P318